BROWNSVILLE, Texas - Some new hope for many patients with Lung cancer.
Two promising new studies suggest combining Immune Therapy drugs with chemotherapy may improve survival. Researchers at New York University found adding Keytruda to chemotherapy doubled overall survival of patients with non-small cell lung cancer; the most common type of the disease.
A Johns Hopkins University study also found patients treated with Opdivo were less likely to have their cancer progress after one year.
Immunotherapy works by harnessing the body's immune system to attack tumors.